Resveratrol Inhibits Nucleosome Binding and Catalytic Activity of PARP1

Resveratrol Inhibits Nucleosome Binding and Catalytic Activity of PARP1

The natural polyphenol resveratrol is a biologically active compound that interacts with DNA and affects the activity of some nuclear enzymes. Its effect on the interaction between nucleosomes and poly(ADP-ribose) polymerase-1 (PARP1) and on the catalytic activity of PARP1 was studied using Western...

Full description

Saved in:

Bibliographic Details
Main Authors:	Daria O. Koshkina, Natalya V. Maluchenko, Anna N. Korovina, Angelina A. Lobanova, Alexey V. Feofanov, Vasily M. Studitsky
Format:	Article
Language:	English
Published:	MDPI AG 2024-11-01
Series:	Biomolecules
Subjects:	poly(ADP-ribose) polymerase-1 PARP1 nucleosome resveratrol spFRET Western blotting
Online Access:	https://www.mdpi.com/2218-273X/14/11/1398
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Poly(ADP-ribose)polymerase 2 is zinc-dependent enzyme and nucleosome reorganizer
by: Natalya Maluchenko, et al.
Published: (2025-06-01)

ADP-ribose hydrolases: biological functions and potential therapeutic targets
by: Jingpeng Wang, et al.
Published: (2024-01-01)

Impact of Poly(ADP-Ribose) Polymerase (PARP) and Immune Checkpoint Inhibitor Combinations on the Viability of Triple-Negative Breast Cancer Cells
by: Tusha Sharma, et al.
Published: (2024-04-01)

The role of Poly-ADP ribose polymerase (PARP) enzymes in chemotherapy-induced cognitive impairments – parallels with other neurodegenerative disorders
by: Dahlia A. Ordaz, et al.
Published: (2025-06-01)

Discovery of novel PARP1/NRP1 dual-targeting inhibitors with strong antitumor potency
by: Juanjuan Liu, et al.
Published: (2024-11-01)

Therapeutic advances and application of PARP inhibitors in breast cancer
by: Teng Zhou, et al.
Published: (2025-07-01)

PARP inhibitors are a new area in the treatment of breast cancer
by: V. P. Letyagin
Published: (2014-08-01)

Blast‐Overpressure Induced Modulation of PARP‐SIRT‐NRF2 Axis in Stress Signaling of Astrocytes and Microglia
by: Vijaya Prakash Krishnan Muthaiah, et al.
Published: (2025-01-01)

PARP inhibitors as first-line maintenance therapy in ovarian cancer: recommendations from an expert panel from Brazil
by: Aknar FC Calabrich, et al.
Published: (2023-04-01)

Protein–Protein Interactions in Base Excision Repair
by: Govardhan Rathnaiah, et al.
Published: (2025-06-01)

The linker histone chaperone Prothymosin α (PTMA) is essential for efficient DNA damage repair and the recruitment of PARP1
by: Ciara A. McKnight, et al.
Published: (2025-06-01)

Preclinical studies of a PARP-targeted theranostic radiopharmaceutical for pancreatic cancer
by: Jie Gao, et al.
Published: (2025-05-01)

PARP inhibitors elicit a cellular senescence mediated inflammatory response in homologous recombination proficient cancer cells
by: Misato Kamii, et al.
Published: (2025-05-01)

PRMT1 inhibitor MS023 suppresses RNA splicing to sensitize small cell lung cancer to DNA damaging agents
by: Mansi K. Aparnathi, et al.
Published: (2025-08-01)

YY1 drives PARP1 expression essential for PARylation of NONO in mRNA maturation during neuroblastoma progression
by: Chunhui Yang, et al.
Published: (2024-12-01)

Correction: Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review
by: Jiajun Li, et al.
Published: (2025-07-01)

Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review
by: Jiajun Li, et al.
Published: (2025-07-01)

Bioinformatics-based identification of key genes for Olaparib resistance in breast cancer: prognostic implications and therapeutic relevance
by: Kezhen Shen, et al.
Published: (2025-06-01)

PARP inhibitor‐based treatment in metastatic, castration‐resistant prostate cancer (mCRPC): A systematic review and meta‐analysis
by: Michela Roberto, et al.
Published: (2025-01-01)

PARP enzymes and mono-ADP-ribosylation: advancing the connection from interferon-signalling to cancer biology
by: Barbara Morone, et al.
Published: (2024-01-01)

Evaluation of plasma nucleosome concentrations and the effect of pre-analytical variables in healthy cats
by: Emily Westerback, et al.
Published: (2025-05-01)

Natural pentafuranosylnucleos(t)ides and their analogs: structure, functions, synthesis, and perspective of medical application
by: Dmitrii Platov, et al.
Published: (2025-05-01)

Variations in flanking or less conserved positions of Reb1 and Abf1 consensus binding sites lead to major changes in their ability to modulate nucleosome sliding activity
by: Fernanda Raiqueo, et al.
Published: (2025-07-01)

Colon-Targeted Poly(ADP-ribose) Polymerase Inhibitors Synergize Therapeutic Effects of Mesalazine Against Rat Colitis Induced by 2,4-Dinitrobenzenesulfonic Acid
by: Changyu Kang, et al.
Published: (2024-12-01)

Poly (ADP-Ribose) Polymerase Inhibitor Olaparib-Resistant <i>BRCA1</i>-Mutant Ovarian Cancer Cells Demonstrate Differential Sensitivity to PARP Inhibitor Rechallenge
by: Chi-Ting Shih, et al.
Published: (2024-11-01)

Exploring the radiochemistry of PARP inhibitors: a new era in therapy and imaging
by: Gianluca Destro, et al.
Published: (2025-07-01)

Effect of the Nucleosome-Depleted Region in the Transcribed Regions of <i>Saccharomyces cerevisiae</i> Genes on Exogenous Gene Expression
by: Shuyan Wang, et al.
Published: (2024-12-01)

Mechanisms of DNA Damage Recognition by UDG and PARP1 in the Nucleosome
by: Safwen Ghediri, et al.
Published: (2025-04-01)

OPTIMIZATION OF 2'-О-α-D-RIBOFURANOSYLADENOSINE SYNTHESIS USING THE SIMPLEX PLANNING METHOD
by: V. E. Oslovsky, et al.
Published: (2013-08-01)

The WAC-downWAC domain in the yeast ISW2 nucleosome remodeling complex forms a structural module essential for ISW2 function but not cell viability
by: Ashish Kumar Singh, et al.
Published: (2025-05-01)

Real‐World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1‐2 Pathogenic Variants
by: Michele Milella, et al.
Published: (2025-02-01)

Histone chaperone‐mediated co‐expression assembly of tetrasomes and nucleosomes
by: Kei‐ichi Okimune, et al.
Published: (2021-11-01)

PARP7 as a new target for activating anti-tumor immunity in cancer
by: Katerina Popova, et al.
Published: (2025-03-01)

Circulating Nucleosomes and Histones in the Development of Lung Injury and Sepsis
by: Saugata Dutta, et al.
Published: (2025-02-01)

Deletion of CD38 enhances CD19 chimeric antigen receptor T cell function
by: Kimberly Veliz, et al.
Published: (2024-06-01)

Parp1 deletion rescues cerebellar hypotrophy in xrcc1 mutant zebrafish
by: Svetlana A. Semenova, et al.
Published: (2025-05-01)

PARP9-PARP13-PARP14 axis tunes colorectal cancer response to radiotherapy
by: Rimvile Prokarenkaite, et al.
Published: (2025-07-01)

Pyridazine Based Compounds with PARP-1 Inhibitory Activity
by: Norhan A. Abdelrahman, et al.
Published: (2023-12-01)

Design and synthesis of benzodiazepines as brain penetrating PARP-1 inhibitors
by: Jiang Yu, et al.
Published: (2022-12-01)

PARP-1 as a novel target in endocrine-resistant breast cancer
by: Azzurra Zicarelli, et al.
Published: (2025-06-01)